Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

Completion of Entitlement Offer

Friday, December 8, 2023 1 min read
Key Takeaway: Radiopharm Theranostics has successfully completed its entitlement offer, reflecting strong investor confidence. The company has also provided positive updates on its clinical programs, including the initiation of a Phase 1/2a study for BetaBart (RV-01). Additionally, the recent IND approval from the FDA positions the company favorably for future developments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Completion of entitlement offer indicates strong investor interest.
  • Positive clinical updates across multiple programs enhance company credibility.
  • Recent IND approval from the FDA supports future clinical studies.

Full Press Release Details

• Announcements
• Price Sensitive
• December 8, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• November 26, 2021
• Announcements
• April 22, 2024
• Announcements
• July 16, 2024
• Announcements
• November 29, 2021

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the recent news about Radiopharm Theranostics?

Radiopharm Theranostics has completed its entitlement offer, indicating strong investor interest.

What clinical updates has Radiopharm provided?

The company has shared positive updates across multiple clinical programs, including BetaBart.

What FDA approval did Radiopharm receive?

Radiopharm received IND approval from the FDA to initiate a Phase 1 therapeutic study.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics entitlement offer clinical updates FDA approval BetaBart
Last updated: Dec 8, 2023